JP-2025513593-A5 -

Dates

Publication Date

20260511

Application Date

20230426

Description

All published documents and patent applications referenced herein are incorporated herein by reference to the same extent as each individual published document or patent application is specifically and individually indicated as being incorporated by reference. In embodiments of the present invention, for example, the following items are provided. (Item 1) An antibody or its antigen-binding fragment having specificity for the human B7-H3 (CD276) protein, comprising a heavy chain variable region (VH) including VH CDR1, VH CDR2, and VH CDR3, and a light chain variable region (VL) including VL CDR1, VL CDR2, and VL CDR3, (a) The VH CDR1 comprises the amino acid sequence of SEQ ID NO: 39; The aforementioned VH CDR2 comprises the amino acid sequence of SEQ ID NO: 40; The VH CDR3 comprises the amino acid sequence of sequence number 41, 42, 43, 44, 45, or 46; The VL CDR1 comprises the amino acid sequence of SEQ ID NO: 47, 48, or 49; The aforementioned VL CDR2 comprises the amino acid sequence of SEQ ID NO: 50; The VL CDR3 contains the amino acid sequence of SEQ ID NO: 51. (b) The VH CDR1 comprises the amino acid sequence of SEQ ID NO: 52; The aforementioned VH CDR2 comprises the amino acid sequence of SEQ ID NO: 53; The aforementioned VH CDR3 contains the amino acid sequence of SEQ ID NO: 54; The aforementioned VL CDR1 contains the amino acid sequence of SEQ ID NO: 55; The aforementioned VL CDR2 comprises the amino acid sequence of SEQ ID NO: 56; The VL CDR3 contains the amino acid sequence of SEQ ID NO: 57. (c) The VH CDR1 comprises the amino acid sequence of SEQ ID NO: 33; The aforementioned VH CDR2 contains the amino acid sequence of SEQ ID NO: 34; The aforementioned VH CDR3 comprises the amino acid sequence of SEQ ID NO: 35; The aforementioned VL CDR1 comprises the amino acid sequence of SEQ ID NO: 36; The aforementioned VL CDR2 contains the amino acid sequence of SEQ ID NO: 37; The VL CDR3 contains the amino acid sequence of SEQ ID NO: 38. (d) The VH CDR1 comprises the amino acid sequence of SEQ ID NO: 25; The VH CDR2 comprises the amino acid sequence of SEQ ID NO: 26, 27, or 28; The aforementioned VH CDR3 comprises the amino acid sequence of SEQ ID NO: 29; The aforementioned VL CDR1 contains the amino acid sequence of SEQ ID NO: 30; The VL CDR2 comprises the amino acid sequence of SEQ ID NO: 31; The VL CDR3 contains the amino acid sequence of SEQ ID NO: 32. (e) The VH CDR1 comprises the amino acid sequence of SEQ ID NO: 58; The aforementioned VH CDR2 comprises the amino acid sequence of SEQ ID NO: 59; The aforementioned VH CDR3 comprises the amino acid sequence of SEQ ID NO: 60; The aforementioned VL CDR1 comprises the amino acid sequence of SEQ ID NO: 61; The aforementioned VL CDR2 comprises the amino acid sequence of SEQ ID NO: 62; The VL CDR3 contains the amino acid sequence of SEQ ID NO: 63. (f) The VH CDR1 comprises the amino acid sequence of SEQ ID NO: 64; The VH CDR2 comprises the amino acid sequence of SEQ ID NO: 65 or 66; The aforementioned VH CDR3 contains the amino acid sequence of SEQ ID NO: 67; The aforementioned VL CDR1 comprises the amino acid sequence of SEQ ID NO: 68; The aforementioned VL CDR2 contains the amino acid sequence of SEQ ID NO: 69; The VL CDR3 contains the amino acid sequence of SEQ ID NO: 70. (g) The VH CDR1 comprises the amino acid sequence of SEQ ID NO: 71; The VH CDR2 comprises the amino acid sequence of SEQ ID NO: 72, 73, or 74; The aforementioned VH CDR3 contains the amino acid sequence of SEQ ID NO: 75; The aforementioned VL CDR1 comprises the amino acid sequence of SEQ ID NO: 76; The aforementioned VL CDR2 contains the amino acid sequence of SEQ ID NO: 77; The aforementioned VL CDR3 contains the amino acid sequence of SEQ ID NO: 78. (h) The VH CDR1 comprises the amino acid sequence of SEQ ID NO: 79; The aforementioned VH CDR2 comprises the amino acid sequence of SEQ ID NO: 80; The aforementioned VH CDR3 comprises the amino acid sequence of SEQ ID NO: 81; The aforementioned VL CDR1 comprises the amino acid sequence of SEQ ID NO: 82; The aforementioned VL CDR2 contains the amino acid sequence of SEQ ID NO: 83; The VL CDR3 contains the amino acid sequence of SEQ ID NO: 84, (i) The VH CDR1 comprises the amino acid sequence of SEQ ID NO: 85; The VH CDR2 comprises the amino acid sequence of SEQ ID NO: 86 or 87; The aforementioned VH CDR3 comprises the amino acid sequence of SEQ ID NO: 88; The aforementioned VL CDR1 comprises the amino acid sequence of SEQ ID NO: 89; The VL CDR2 comprises the amino acid sequence of SEQ ID NO: 90; The VL CDR3 contains the amino acid sequence of SEQ ID NO: 91, (j) The VH CDR1 comprises the amino acid sequence of SEQ ID NO: 92; The VH CDR2 comprises the amino acid sequence of SEQ ID NO: 93, 94, 95, or 96; The aforementioned VH CDR3 contains the amino acid sequence of SEQ ID NO: 97; The aforementioned VL CDR1 comprises the amino acid sequence of SEQ ID NO: 98; The VL CDR2 comprises the amino acid sequence of SEQ ID NO: 99 or 100; The VL CDR3 contain